Please ensure Javascript is enabled for purposes of website accessibility
Todd Campbell

Todd Campbell


Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles


Why Your Social Security Income Could Increase 5% (or More) in 2022

Inflation could mean retirees will pocket the biggest Social Security cost-of-living (COLA) adjustment in decades.


Retiring at 70? Here's the Maximum You Can Collect in Social Security Income

If you're planning to collect Social Security at age 70 this year, then this is the most you can collect in monthly benefits.


Here Are Warren Buffett's Biggest Stock Picks

Berkshire Hathaway's top holdings include a technology stock, two financial giants, and two of the best known consumer brands companies in the world.


Could Social Security Recipients Get a Big Raise Next Year?

Social Security payments could be heading higher because of inflation.

Top Stocks Warren Buffett Just Bought

These were Berkshire Hathaway's biggest buys during Q2, 2021.


Social Security Benefits Could Skyrocket Next Year

Social Security payments could increase by the largest amount in nearly 40 years in 2022.


Retiring Early? Here's The Top Social Security Income at Age 62

If you're planning to begin receiving Social Security at age 62 this year, then this is the maximum you can collect in benefits.


Here's the Maximum Social Security Benefit in 2021

Social Security's maximum payment may surprise you.


Here's How Much the Average Person Collects in Social Security Benefits

The average amount Social Security recipients receive monthly may surprise you.


Social Security Recipients Could Get a Big Raise Next Year

Social Security payments could climb significantly this year because of inflation.


Moderna Files for FDA Approval of Its COVID Vaccine in Teens

The company hopes to secure Emergency Use Authorization for its vaccine in children ages 12 to 18.


Vertex Pharmaceuticals Nabs Key FDA Approval in Cystic Fibrosis

The Food and Drug Administration has expanded eligibility for Trikafta to include amenable cystic fibrosis patients aged 6 to 11.


Merck Cuts a Billion-Dollar COVID Deal

The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug.


Senator Takes Aim at Biogen's New Alzheimer's Drug

Sen. Ron Wyden calls Aduhelm's $56,000 price tag "unconscionable."


Biogen's New Alzheimer's Drug Will Cost $56,000 Per Year

Biogen set the list price for Aduhelm, its newly approved treatment, and is collaborating with CVS to improve screening for the disease.


Bluebird bio Can Restart Halted Clinical Trials

The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia.


Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment

A trial examining the use of Novocure's tumor-treating field technology in non-small cell lung cancer patients could enroll fewer patients over a shorter period, based on recommendations by an independent committee.


bluebird bio Says Its Drug "Unlikely" to Have Caused Blood Cancer

A clinical hold on the biotech company could be lifted following Bluebird's results.


Warren Buffett Just Bought These Stocks

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.


Amazon Opens an Online Pharmacy

The e-commerce giant's new pharmacy will deliver prescription drugs throughout most of the U.S.